Medical Case Studies
Subscribe to MCS
Full Name*
Email Address*

Article Number - D4F2EFC504


Vol.2(1) , January 2011

ISSN: 2141-6532



Review

Treatment advances and future directions in stages II and III colon cancer



El Mehdi Tazi and Hassan Errihani
  • El Mehdi Tazi and Hassan Errihani
  • Department of Medical Oncology, National Institute of Oncology, Rabat, Kingdom of Morocco
  • Google Scholar







 Accepted: 02 September 2010  Published: 31 January 2011

Copyright © 2011 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N (2009). Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol., 27: 3385-3390.
http://dx.doi.org/10.1200/JCO.2009.21.9220
PMid:19414665 PMCid:PMC2717026
 
American Cancer Society (2009). Cancer Facts and Figures. Atlanta: American Cancer Society; 2009. Available at: www.cancer.org/downloads/STT/500809web.pdf.
 
American Joint Committee on Cancer (2010). AJCC Cancer Staging Manual. 7th ed. ISBN: 978-0-387 88440-0.
http://dx.doi.org/10.1007/978-0-387-88443-1
http://dx.doi.org/10.1007/978-0-387-88441-7
 
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Laroze AB, Flesch M, Buyse M, Gramont A (2003). A semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J. Clin. Oncol., 21: 2896-2903.
http://dx.doi.org/10.1200/JCO.2003.10.065
PMid:12885807
 
Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Mathieu NT, Laroze AB, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, Gramont AD (2007). Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J. Clin. Oncol., 25(24): 3732-3738.
http://dx.doi.org/10.1200/JCO.2007.12.2234
PMid:17704423
 
Andre´ T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, Gramont AD (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol., 27(19): 3109-3116. Available at: http://www.cancer.gov/newscenter/pressreleases/CetuximabClosure.
http://dx.doi.org/10.1200/JCO.2008.20.6771
PMid:19451431
 
Bokemeyer C, Bondarenko I, Hartmann JT, Makhson A, Aparicio J, Braud FD, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 27: 663-671.
http://dx.doi.org/10.1200/JCO.2008.20.8397
PMid:19114683
 
Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br. J. Cancer., 101: 998-1004.
http://dx.doi.org/10.1038/sj.bjc.6605239
PMid:19672255 PMCid:PMC2743363
 
Chun P, Wainberg ZA (2009). Adjuvant chemotherapy for stage II colon cancer: the role of molecular markers in choosing therapy. Gastrointest Cancer Res., 3: 191-196.
PMid:20084160 PMCid:PMC2806802
 
Cutsem EV, Kohne CH, Hitre E, Zaluski J, Chien CC, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med., 360: 1408-1417.
http://dx.doi.org/10.1056/NEJMoa0805019
PMid:19339720
 
Cutsem EV, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham Cl, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D(2009). Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol., 27: 3117-3125.
http://dx.doi.org/10.1200/JCO.2008.21.6663
PMid:19451425
 
Cutsem EV, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Laethem JV, Maurel J, Richardson G, Wolf M, Amado RG (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol., 25: 1658–1664.
http://dx.doi.org/10.1200/JCO.2006.08.1620
PMid:17470858
 
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355(9209): 1041–1047.
http://dx.doi.org/10.1016/S0140-6736(00)02034-1
 
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Baruge ME, Humblet Y, Cunningham D, Wolf M, Gansert J (2009). Randomized phase 3 study of panitumumab with FOLFOX4 vs FOLFOX4 alone as first-line treatment in patients with metastatic colorectal cancer: the PRIME trial. Eur. J. Cancer Suppl., 7(6): 1-3.
 
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA,Christensen JG, Kerbel RS (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell., 15: 232–239.
http://dx.doi.org/10.1016/j.ccr.2009.01.021
PMid:19249681
 
Folkman J (1992). The role of angiogenesis in tumor growth. Semin. Cancer Biol., 3(2): 65-71.
PMid:1378311
 
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol.,25: 1539 –1544.
http://dx.doi.org/10.1200/JCO.2006.09.6305
PMid:17442997
 
Gill S, Loprinzi CL, Sargent DJ,Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Seitz JF, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004). Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol., 22: 1797-1806.
http://dx.doi.org/10.1200/JCO.2004.09.059
PMid:15067028
 
Goldberg RM, Tabah-Fisch I, Bleiberg H, Gramont AD, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ (2006). Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J. Clin. Oncol., 24: 4085-4091.
http://dx.doi.org/10.1200/JCO.2006.06.9039
PMid:16943526
Grady WM, Carethers JM (2008). Genomic and epigenetic instability in colorectal pathogenesis. Gastroenterology., 135: 1079-1099.
http://dx.doi.org/10.1053/j.gastro.2008.07.076
PMid:18773902 PMCid:PMC2866182
 
Gramont AD, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Funes CH, Cervantes A, Freyer G, Papamichael D, Bail NL, Louvet C, Hendler D, Braud FD, Wilson C, Morvan F, Bonetti A (2000). Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J. Clin. Oncol., 18(16): 2938–2947.
PMid:10944126
 
Gray R, Barnwell J, McConkey C, Kerr D (2007).Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet., 370(9604): 2020–2029.
http://dx.doi.org/10.1016/S0140-6736(07)61866-2
 
Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ (2005). Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J. Clin. Oncol., 23: 8671–8678.
http://dx.doi.org/10.1200/JCO.2004.00.5686
PMid:16314627
 
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 350: 2335–2342.
http://dx.doi.org/10.1056/NEJMoa032691
PMid:15175435
 
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF (2005). Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol., 23(16): 3697–3705.
http://dx.doi.org/10.1200/JCO.2005.05.112
PMid:15738537
 
Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ (2007). Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. J. Clin. Oncol., 25: 767–772.
http://dx.doi.org/10.1200/JCO.2006.05.8172
PMid:17228023
 
Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N (2007). Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol., 25: 2198–2204.
http://dx.doi.org/10.1200/JCO.2006.08.2974
PMid:17470851
 
Lembersky BC, Wieand HS, Petrelli JS, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N (2006). Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol., 24(13): 2059–2064.
http://dx.doi.org/10.1200/JCO.2005.04.7498
PMid:16648506
 
Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N (2006). Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J. Clin. Oncol., 24(13): 2059 –2064.
http://dx.doi.org/10.1200/JCO.2005.04.7498
PMid:16648506
 
Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009). Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell., 15: 167–170.
http://dx.doi.org/10.1016/j.ccr.2009.02.007
PMid:19249675
 
Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H (1999). Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs. Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03 and C-04). J. Clin. Oncol., 17: 1349 –1355.
PMid:10334518
 
Maughan TS, Adams RA, Smith C (2009). COIN: A three-arm randomised controlled trial comparing either continuous chemotherapy plus cetuximab or intermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer. ESMO Berl.; LBA6.
 
McCleary JNA, Meyerhardt J, Green E, Yothers G, Gramont AD, Cutsem EV, O'Connell M, Twelves C, Saltz L, Sargent D (2009). Impact of older age on the efficacy of newer adjuvant therapies in 12500 patients with stage II/III colon cancer: findings from the ACCENT database. J. Clin. Oncol., 27(15S): 4010.
 
Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990).Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 322: 352–358.
http://dx.doi.org/10.1056/NEJM199002083220602
PMid:2300087
 
O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS (1997).Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J. Clin. Oncol., 15: 246–250.
PMid:8996149
 
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vi-als F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell., 5: 220–231.
http://dx.doi.org/10.1016/j.ccr.2009.01.027
PMid:19249680 PMCid:PMC2874829
 
Peeters M, Price TJ, Hotko Y, Wilson G, Ducreux M, Cervantes A, André T, Lordick F, Collins S, Shing M (2009). Randomized phase III study of panitu mumab with FOLFIRI vs FOLFIRI alone as -line treatment in patients with metastatic colorectal cancer. Eur. J. Cancer Suppl., 7: 9.
http://dx.doi.org/10.1016/S1359-6349(09)72049-X
 
Popat S, Hubner R, Houlston RS (2005). Systematic review of microsatellite instability and colorectal prognosis. J. Clin. Oncol., 23: 609–618.
http://dx.doi.org/10.1200/JCO.2005.01.086
PMid:15659508
 
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, Amy J,Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Dongsheng T, Redston M, Gallinger S (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med., 349: 247–257.
http://dx.doi.org/10.1056/NEJMoa022289
PMid:12867608 PMCid:PMC3584639
 
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Cutsem EV, Bosman F (2010). Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol., 28: 466–474.
http://dx.doi.org/10.1200/JCO.2009.23.3452
PMid:20008640
 
Roth AD, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Cutsem EV, Bosman F (2009). Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J. Clin. Oncol., 27(15S): 4002.
 
Sakamoto J, Ohashi Y, Hamada C, Buyse M, Burzykowski T, Piedbois P (2004). Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J. Clin. Oncol., 22: 484–492.
PMid:14752071
 
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol., 26(12): 2013–2019.
http://dx.doi.org/10.1200/JCO.2007.14.9930
PMid:18421054
 
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 343: 905–914.
http://dx.doi.org/10.1056/NEJM200009283431302
PMid:11006366
 
Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields ALA, Mayer RJ (2007). Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol., 25(23): 3456–3461.
http://dx.doi.org/10.1200/JCO.2007.11.2144
PMid:17687149
 
Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Shepherd LE, Seitz JF, Francini G (2001). A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med., 345: 1091–1097.
http://dx.doi.org/10.1056/NEJMoa010957
PMid:11596588
 
Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A, Gallinger S (2008). Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J. Clin. Oncol., 26: 4008.
Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, Gramont AD (2005). Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol., 23: 8664–8670.
http://dx.doi.org/10.1200/JCO.2005.01.6071
PMid:16260700
 
Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, Plant BL, Amy J, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE (2006). Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology, 131: 729 –737.
http://dx.doi.org/10.1053/j.gastro.2006.06.005
PMid:16952542
 
Tejpar S, Bosman F, Delorenzi M, Fiocca R, Yan P, Klingbiel D, Dietrich D, Cutsem EV, Labianca R, Roth AD (2009). Microsatellite instability (MSI) in stage II and III colon cancer treated with 5-FU-LV or 5-FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J. Clin. Oncol., 27(15S): 4001.
 
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mignard DM, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, Gramont AD (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol., 22(2): 229 –237.
http://dx.doi.org/10.1200/JCO.2004.05.113
PMid:14657227
 
Twelves C, Wong A,Nowacki MP, Markus A, Burris H,Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, Weitz J, Koch M, Debus J (2005). Colorectal cancer. Lancet., 365: 153– 165.
http://dx.doi.org/10.3816/CCC.2005.n.021
PMid:16098250
 
Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B (1999). Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol., 17(11): 3553–3559.
PMid:10550154
 
Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, Feherenbacher L, O'Reilly S, Allegra CJ (2009). A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 [abstract LBA4]. J. Clin. Oncol., 27: 18s.
 
Ychou M, Hohenberger W, Thezenas S, Navarro M, Maure J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Choi CK, Santoro A (2009). A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol., 20: 1964–1970.
http://dx.doi.org/10.1093/annonc/mdp236
PMid:19567451
 
Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, Gramont AD, Tiret E, Dumont S, Gayet B, Validire P, Fléjou JF, Duval A, Praz F (2010). Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol., 21: 772–780.
http://dx.doi.org/10.1093/annonc/mdp383
PMid:19833818

 


APA (2011). Treatment advances and future directions in stages II and III colon cancer. Medical Case Studies, 2(1), .
Chicago El Mehdi Tazi and Hassan Errihani. "Treatment advances and future directions in stages II and III colon cancer." Medical Case Studies 2, no. 1 (2011): .
MLA El Mehdi Tazi and Hassan Errihani. "Treatment advances and future directions in stages II and III colon cancer." Medical Case Studies 2.1 (2011): .
   
DOI
URL http://academicjournals.org/journal/MCS/article-abstract/D4F2EFC504

Subscription Form